Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Novartis Pharmaceuticals · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
multiple-sclerosis
multiple sclerosis, ofatumumab, relapsing multiple sclerosis, relapsing-remitting ms, ms therapy, rms, relapsing ms, glatiramer acetate, ifnβ-1b, ifnβ-1a, peg-ifnβ-1a, teriflunomide
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 876618
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.